Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.42 |
| ▸ | HSD17B14 | Q9BPX1 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 2/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8963489 | 0.87 | CKS1B (0.47) | ALDH1A1KDM4ESMN1; SMN2PRKCQHSD17B14 | |
| SCHEMBL8963362 | 0.85 | ALDH1A1 (0.46) | JAK2JAK1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL8963437 | 0.85 | PRKCQ (0.44) | ALDH1A1KDM4ESMN1; SMN2PRKCQHSD17B14 | |
| SCHEMBL8963478 | 0.85 | KDM4E (0.49) | ALDH1A1KDM4ESMN1; SMN2PRKCQHSD17B14 | |
| SCHEMBL8963368 | 0.85 | PRKCQ (0.44) | ALDH1A1KDM4ESMN1; SMN2PRKCQHSD17B14 | |
| SCHEMBL8963547 | 0.85 | ALDH1A1 (0.49) | ALDH1A1KDM4ESMN1; SMN2PRKCQHSD17B14 | |
| SCHEMBL8963422 | 0.85 | ALDH1A1 (0.43) | ALDH1A1KDM4ESMN1; SMN2PRKCQHSD17B14 | |
| SCHEMBL8963072 | 0.84 | PRKCQ (0.48) | ALDH1A1KDM4ESMN1; SMN2PRKCQHSD17B14 | |
| SCHEMBL8963254 | 0.84 | PRKCQ (0.46) | ALDH1A1KDM4ESMN1; SMN2PRKCQHSD17B14 | |
| SCHEMBL8963417 | 0.83 | PRKCQ (0.46) | ALDH1A1KDM4ESMN1; SMN2PRKCQHSD17B14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-8741931-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-03 | — | — | US | disclosed |
| US-20120214799-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110077237-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | JAK2 133/4885JAK1 100/4885TYK2 460/4885 |
| US-20120214799-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | JAK2 133/4885JAK1 100/4885TYK2 460/4885 |
| US-20110077237-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | JAK2 133/4885JAK1 100/4885TYK2 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.